Medical cannabis remains difficult to attain in healthcare under the UK government, but it holds great promise for both NHS patients and the economy

The UK government can ill afford to disregard the explosion of interest in and potential widespread benefits of the medicinal cannabis sector. Expected to top $1.3 billion by 2024, Tej Virk, CEO at Akanda, writes to the new PM: “Can we please finally have a conversation about medical cannabis?”

The value alone to the economy and to job creation is enormous, aside from the health benefits to patients suffering from a range of physical and psychological conditions which have been shown to respond to cannabis-based medication. The sector nevertheless needs the sanction and support of the UK government with the application of due process, to permit the wider use of these products.

Read the full story at openaccessgovernment.org